Larazotide, a therapy known to treat celiac disease, shows promise as a safe treatment for multisystem inflammatory syndrome in children linked to COVID-19, enhancing recovery and symptom resolution.

In a small trial, Mass General Brigham researchers have found that a drug designed to treat celiac disease supported a more rapid return to normal activities for patients following COVID.